Single doses of canvuparatide, an injectable hormone replacement treatment being developed by MBX Biosciences for chronic hypoparathyroidism, appeared to be safe in healthy adults and were long-acting in the bloodstream, supporting the once-weekly dosing regimen now being tested in later-stage trials. These data come from the first…
MBX Biosciences is advancing its experimental therapy canvuparatide (MBX 2109) toward a Phase 3 trial in adults with chronic hypoparathyroidism, following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). An End-of-Phase 2 meeting is typically held after a Phase 2 study to determine whether a…
Discussion
Editor’s note: This story includes a mention of suicide. If you or someone you know needs help, the national suicide and crisis lifeline in the U.S. is available by calling or texting 988. There is also an online chat at 988lifeline.org. Internationally, find a suicide…
Discussion
My world teetered as a calcium crash struck in 2016, leaving me breathless and confused. It was a scary time for my family, especially for my son Harrison, who was starting high school. It was also a pivotal moment for me, altering my path and propelling me into a desperate…
Get regular updates to your inbox.
